Remove 2022 Remove Disease Remove Hospital Remove Nuclear Medicine
article thumbnail

Society of Nuclear Medicine and Molecular Imaging Names Helen Nadel, MD, FRCPC, of Stanford, as President, Announces New Officers at SNMMI 2023 Annual Meeting

Imaging Technology

Urbain, MD, PhD, FASNC , professor of radiology/nuclear medicine and medicine, vice chair of theranostics, and director of nuclear medicine at Roswell Park Cancer Center at the University of Buffalo , Buffalo, New York. and ‘How can we ensure diversity in all parts of the nuclear medicine family?’

article thumbnail

FAPI-PET bests FDG-PET in detecting gastrointestinal cancer

AuntMinnie

Fibroblast activation protein inhibitor (FAPI)-PET/CT appears superior to standard FDG-PET/CT for detecting gastrointestinal cancer, with higher radiotracer uptake seen in most tumors, according to a study published October 26 in the Journal of Nuclear Medicine. Image courtesy of the Journal of Nuclear Medicine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Prostate Cancer Treatment Study at SNMMI 2023 Finds Improved Patient Outcomes with Personalized Dosing

Imaging Technology

christine.book Thu, 06/29/2023 - 12:17 June 29, 2023 — A study presented this week during the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, SNMMI 2023 , found that personalized dosing of men with prostate cancer resulted in improved patient outcomes. Vincent's Hospital in Sydney, Australia.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman.

article thumbnail

The rise of theranostics: Part 2 -- Moving into communities

AuntMinnie

Thomas Hope, MD, a radiologist and nuclear medicine physician at the University of California, San Francisco (UCSF), said that approval of lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) radioligand has driven a marked interest and excitement about theranostics and radioligand therapies (RLT). Hope added. Hope added.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman.

article thumbnail

GE HealthCare Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI

Imaging Technology

“We can’t treat what we don’t see, which is why we require precise image quality to help diagnose, plan treatment for, and monitor disease,” explains Prof. Flavio Forrer , MD, PhD, Chairman of Nuclear Medicine in the Division of Radiology and Nuclear Medicine at Kantonsspital St. Gallen in Switzerland [vii].